Biochem/physiol Actions
Primary TargetPDGFR kinase
Target IC50: 500 nM against PDGFR kinase
Reversible: yes
Product competes with ATP.
Cell permeable: yes
General description
A cell-permeable, reversible, ATP-competitive, and selective inhibitor of platelet-derived growth factor (PDGF) receptor kinase (IC50 = 500 nM) and PDGF-dependent DNA synthesis (IC50 = 2.5 µM) in Swiss/3T3 cells. Has no effect on EGF receptor autophosphorylation and shows only a weak effect on EGF- or insulin-stimulated DNA synthesis. A potent blocker of smooth muscle cell proliferation.
Selectively inhibits platelet-derived growth factor (PDGF) receptor kinase (IC50 = 500 nM) and the PDGF-dependent DNA synthesis (IC50 = 2.5 µM) in Swiss 3T3 cells. Has no effect on epidermal growth factor (EGF) receptor autophosphorylation and shows only a weak effect on EGF- or insulin-stimulated DNA synthesis.
Legal Information
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
Other Notes
Banai, S., et al. 1998. Circulation 97, 1960.Levitzki, A., and Gazit, A. 1995. Science267, 1782.Kovalenko, M., et al. 1994. Cancer Res.54, 6106.
Packaging
5 mg in Plastic ampoule
Reconstitution
Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 1 month at -20°C.
Warning
Toxicity: Standard Handling (A)
This product has met the following criteria: